Bio-techne Corp · NASDAQ:TECH
Bio-techne — Investor Presentation (June 2021)
22 slides from Bio-techne's investor presentation, June 2021
Slide 1: Where Science Intersects Innovation
WHERE SCIENCE INTERSECTS INNOVATION TM Corporate Presentation June 2021 © 2021 Bio-Techne®. All rights reserved.
Slide 2: Safe Harbor Cautionary Statements
S AF E HAR B O R C A U T I O N A R Y S TAT E M E N T S This presentation contains “forward-looking statements” within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward-looking and made pursuant to the safe
Slide 3: Business Overview
PROTEINS ANTIBODIES BUSINESS 10% 6% 2% INSTRUMENTS SERVICES R OYA LT I E S OVERVIEW PRESIDENT AND CEO Chuck Kummeth AUTOMATED PROTEIN ANALYSIS IMMUNOASSAYS HEADQUARTERS Minneapolis, MN NUMBER OF EMPLOYEES ~2,600 TISSUE PATHOLOGY LIQUID BIOPSY WORLDWIDE PRESENCE 35 Locations FY2020 REVENUES $739M 82
Slide 4: FY20 Revenue by Customer Type & Geography
F Y 2 0 R E V E N U E B Y C U STOM ER TYPE & GEOGRAPHY $739M 22% 18% OEM 17% ASIA DISTRIBUTORS 23% 57% AMERICAS ACADEMIA 25% EMEA 38% PHARMA/BIOTECH © 2021 Bio-Techne®. All rights reserved. 4
Slide 5: Four Key Strategies for Sustained Growth
F O U R K E Y S T R AT E G I E S F O R S U S TA I N E D GR OWT H GEOGRAPHIC CORE PRODUCT GAP FILLING M&A C U LT U R E E X PA N S I O N I N N O VAT I O N AND MARKET C R E AT I O N E X PA N S I O N A N D TA L E N T © 2021 Bio-Techne®. All rights reserved. 5
Slide 6: Laying the Foundation for a Sustainable Future
L AY I N G T H E F O U N D AT I O N F O R A S U S TA I N A B L E F U T U R E E N V I R O N M E N TA L SOCIAL GOVERNANCE • Continual progress toward sustainability at • Diverse and inclusive workplace: • Board membership includes: largest global manufacturing site: • 50% of global workforce are femal
Slide 7: Large Addressable End Markets: ~$14B-$20B
LARGE ADDRESSABLE END MARKETS: ~$14B -$20B MARKET BIO-TECHNE BIO-TECHNE END MARKETS MARKET SIZE G R O W T H R AT E G R O W T H R AT E MARKET P E N E T R AT I O N PROTEOMIC RESEARCH REAGENTS ~ $3 B MID-SINGLE DIGIT 9 %- 1 1 % ~10% P R O T E O M I C A N A LY T I C A L $2 B - $3 B MID-SINGLE ~15% ~10%
Slide 8: Our Segment Structure
OUR SEGMENT STRUCTURE PROTEIN SCIENCES DIAGNOSTICS & GENOMICS PROTEOMIC PROTEOMIC DIAGNOSTIC DIAGNOSTIC GENOMICS RESEARCH A N A LY T I C A L REAGENTS KITS Advanced, tissue morphology REAGENTS TOOLS Develops and manufactures Develops and manufactures friendly RNA IN SITU hybridization (ISH) assay for
Slide 9: Protein Sciences
PROTEIN SCIENCES PROTEINS ANTIBODIES I M M U N O A S S AY S INSTRUMENTS © 2021 Bio-Techne®. All rights reserved. 9
Slide 10: Proteomic Research Reagents
PROTEOMIC RESEARCH REAGENTS Bio-Techne Citations* 20,000 PROTEINS ANTIBODIES • Proteins sold with optimal bio-activity assay, highest quality, lot-to-lot consistency • Extensive monoclonal antibody production capabilities to generate application specific 0 antibodies 2015 2016 2017 2018 2019 • Full
Slide 11: Key Proteomic Research Reagent Applications
K E Y P R O T E O M I C R E S E A R C H R E A G E N T A P P L I C AT I O N S PROTEINS ANTIBODIES CELL & GENE THERAPY (GMP CELL IMAGING PROTEINS) BIOMARKERS IN CELL GROWTH & BLOCKING/ I M M U N O A S S AY DISEASE D I F F E R E N T I AT I O N A C T I VAT I O N MONITORING S P E C I A LT Y M E D I A ANT
Slide 12: Cell & Gene Therapy Applications
C E L L & G E N E T H E R A P Y A P P L I C AT I O N S G M P P R O T E I N FA C I L I T Y • 1Q21 Grand opening • 61,000 Sq. Foot state- of-the-art facility • Qualification process underway • Commercial GMP production runs in- progress • Differentiated products to meet cell & gene therapy customer ne
Slide 13: Proteomic Analytical Tools
P R O T E O M I C A N A LY T I C A L T O O L S I M M U N O A S S AY SIMPLE PLEX • Market leading portfolio of single analyte • High quality, reproducible immunoassays with no & multiplex immunoassays manual intervention or operator bias TAM: $2B-$3B • Key supplier to Luminex testing platform • Sub-p
Slide 14: Diagnostics & Genomics
DIAGNOSTICS & GENOMICS TISSUE BIOPSY LIQUID BIOPSY DIAGNOSTIC DIAGNOSTIC A N D S PAT I A L TEST AND KITS REAGENTS A N A LY S I S DI SCOVERY P L AT F O R M © 2021 Bio-Techne®. All rights reserved. 14
Slide 15: Tissue Pathology
T I S S U E PAT H O L O G Y TAM: ~$1B-$2B MARKET GROWTH: MID-SINGLE DIGIT BIO-TECHNE MARKET SHARE: 5% BIO-TECHNE GROWTH: 20%-30% • RNAscope technology is novel in-situ hybridization (ISH) assay for detection of target RNA within intact cells. • Proprietary probe design amplifies target-specific sign
Slide 16: Exosome Based Liquid Biopsy
EXOSOME BASED LIQUID BIOPSY C O M P L E T E P R O F I L I N G O F E X O S O M A L M O L E C U L A R S I G N AT U R E S : • PLASMA • PLASMA • SERUM 1) • SERUM 1) • CSF • URINE 2) 2) • SALIVA EXOSOME RELEASE BIOFLUID E X O S O M E I S O L AT I O N BIOMARKER • Active process from living cells, part of
Slide 17: Diagnostic Kits
DIAGNOSTIC KITS TAM: ~$1B MARKET GROWTH: LOW-DOUBLE DIGIT BIO-TECHNE MARKET SHARE: <5% BIO-TECHNE GROWTH: >20% • Acquisition completed on April 6, 2021. Terms include $215 million in cash plus $105 in contingent consideration. In CY2020, Asuragen generated >$30M in revenue • Market leading developer
Slide 18: Diagnostic Reagents
DIAGNOSTIC REAGENTS TAM: ~$1B-$2B • Market leading supplier of clinical controls, calibrators and kits for the diagnostics MARKET GROWTH: MID-SINGLE DIGIT industry BIO-TECHNE MARKET SHARE: ~10% • Recently completed Asuragen acquisition adds portfolio of easy-to-use IVD and RUO BIO-TECHNE GROWTH: 4%-
Slide 19: Cell & Gene Therapy Workflow Solutions
C R O S S C OI M M PA M UNNYE CCEELLLL &T HGEERNAEP YT HOEPRP A OPRYT UWNOI TRIKE FS L O W S O L U T I O N S © 2019 Bio-Techne®. All rights reserved. 19 © 2020 Bio-Techne®. All rights reserved.
Slide 20: Financial Results Under Current Leadership
F I NA NC I A L R ESU LTS U ND E R C U R R E NT L EA D E RSH I P ORGANIC REVENUE A D J U S T E D O P E R AT I N G CASH FROM INCOME($M) 230 GROWTH 263 O P E R AT I O N S ( $ M ) 246 205 17% 244 239 182 170 208 % 10% 198 139 144 143 9 190 137 6% 6% 184 124 4% 4% 169 3% 0% FY 2013 FY 2014 FY 2015 FY 20
Slide 21: Positioned for Strong Financial Performance
P O SI T I O NE D FO R ST RO NG F I NA NC I A L P E R FO R M A NC E ~$1.5B ~$0.6B REVENUE A D J . O P E R AT I N G INCOME $739M $246M $563M $208M $358M $180M ~40% FY14 FY17 FY20 FY25 FY14 FY17 FY20 FY25 Rev CAGR OM% • Proteomic Analytical Tools ~15% • Proteomic Analytical Tools Mid 40s% • Cell & Gen
Slide 22: Thank You
THANK YOU © 2021 Bio-Techne®. All rights reserved. 22